SEA Hero image
SEA Hero image

BATTLE TESTED
IN EOS DISEASE

Backed by real-world, long-term,
and clinical trial evidence—
NUCALA protects your SEA
 patients from exacerbations

Backed by real-world, long-term, and clinical trial evidence—NUCALA protects your SEA patients from exacerbations

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Choose NUCALA for SEA

Choose NUCALA for SEA

Red lung icon

Exacerbation reduction

Trial 2: 53% reduction in exacerbations vs placebo
(P<0.001; Primary Endpoint)1*

Real-world study:

interim analysis at 1 year2†

Down Arrow

71%

reduction

in exacerbations

vs baseline

Primary objective.

Results are descriptive.

See study limitations†

View exacerbation data

Two pills icon

OCS reduction

Trial 3: Greater reduction in daily OCS while maintaining asthma control vs placebo (P=0.008; Primary Endpoint; Weeks 20-24)3‡

Real-world study:

interim analysis at 1 year2†

Down Arrow

75%

reduction

in daily maintenance
OCS dose vs baseline§

Secondary objective.

Results are descriptive.

See study limitations†

See OCS reduction data

Red calendar icon

Long-term data

4.5-year open-label study:
Exacerbation rate 0.68/year (Secondary Endpoint)4II

Associated with

Down Arrow

61%

reduction

in annual exacerbation

rate vs baseline4II

Results are descriptive.

Median duration 3.8 years.2

Review long-term data

†Real-world study: Prespecified interim analysis of a 2-year prospective, observational cohort study at 1 year (N=822). Primary objective (shown above): Post-exposure NUCALA 1.23 vs baseline 4.28 (71% reduction; rate ratio 0.29; 95% CI: 0.26, 0.32). Secondary objective (shown above): Daily median maintenance OCS dose in OCS-dependent patient subgroup (n=298). Post-exposure NUCALA at Weeks 53-56 (n=222) 2.5 mg/day vs baseline 10 mg/day. Results are descriptive. Study limitations: May not reflect final results. Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.2

§Dose assessments based on data captured from medical records or patient recall without documentation of asthma control.2

 

II4.5-year open-label study: Assessed safety, immunogenicity, and efficacy of NUCALA (N=347). Select secondary endpoint: Mean exacerbations/year: 0.68 (95% CI: 0.60, 0.78) with NUCALA + asthma controller in all patients; based on exacerbations reported from the time a patient enrolled until study withdrawal (median duration 3.8 years). Rate prior to study start was 1.74.2,4 Results are descriptive.

*Trial 2: 32-week placebo controlled study (N=576) Primary endpoint: Frequency of exacerbations. NUCALA+SOC 0.83/year, placebo+SOC 1.74/year, P<0.001.

‡Trial 3: 24-week placebo-controlled OCS dose reduction trial (N=135).

 

View full study design and primary endpoint results  

The targeted therapy for 4 eosinophil-driven diseases

NUCALA is for the:

See Important Safety Info

Red checklist icon

Get your patients started with NUCALA

Steps for accessing NUCALA and other helpful resources for your SEA patients and practice

See patient access & support

NUCALA Red Autoinjector icon

Administering NUCALA 

NUCALA gives appropriate patients the option to self-administer at home.

See SEA dosing & administration

CI=confidence interval; ED=emergency department; IL=interleukin; MOA=mechanism of action; OCS=oral corticosteroid; SOC=standard of care.

Next: Eosinophils and MOA in SEA

Request a Rep

Request a Rep

Patient profiles icon

Who is the NUCALA SEA patient?

Red eosinophil Calculator icon

Convert SEA patient lab results with the Eosinophil Calculator